Show simple item record

dc.contributor.authorBery, N
dc.contributor.authorRabbitts, TH
dc.date.accessioned2021-01-13T12:32:48Z
dc.date.issued2019-06-01
dc.identifier.citationCurrent protocols in cell biology, 2019, 83 (1), pp. e83 - ?
dc.identifier.issn1934-2500
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4280
dc.identifier.eissn1934-2616
dc.identifier.doi10.1002/cpcb.83
dc.description.abstractProtein-protein interactions (PPIs) are principle biological processes that control normal cell growth, differentiation, and homeostasis but are also crucial in diseases such as malignancy, neuropathy, and infection. Despite the importance of PPIs in biology, this target class has been very challenging to convert to therapeutics. In the last decade, much progress has been made in the inhibition of PPIs involved in diseases, but many remain difficult such as RAS-effector interactions in cancers. We describe here a protocol for using Bioluminescence Resonance Energy Transfer 2 (BRET2)-based RAS biosensors to detect and characterize RAS PPI inhibition by macromolecules and small molecules. This method could be extended to any other small GTPases or any other PPIs of interest. © 2019 by John Wiley & Sons, Inc.
dc.formatPrint-Electronic
dc.format.extente83 - ?
dc.languageeng
dc.language.isoeng
dc.publisherWiley
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectHumans
dc.subjectras Proteins
dc.subjectImmunoblotting
dc.subjectLuminescent Measurements
dc.subjectProtein Engineering
dc.subjectBiosensing Techniques
dc.subjectEnergy Transfer
dc.subjectHEK293 Cells
dc.titleBioluminescence Resonance Energy Transfer 2 (BRET2)-Based RAS Biosensors to Characterize RAS Inhibitors.
dc.typeJournal Article
rioxxterms.versionofrecord10.1002/cpcb.83
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2019-06
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCurrent protocols in cell biology
pubs.issue1
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Chromosomal Translocations and Intracellular Antibody Therapeutics
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Chromosomal Translocations and Intracellular Antibody Therapeutics
pubs.publication-statusPublished
pubs.volume83
pubs.embargo.termsNo embargo
icr.researchteamChromosomal Translocations and Intracellular Antibody Therapeutics
dc.contributor.icrauthorRabbitts, Terence


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following collection(s)

Show simple item record